ZERO BREEZE Unveils its Revolutionary Mark 3 Portable Air Conditioner at CES 2025

LAS VEGAS, Jan. 8, 2025 /PRNewswire/ -- ZERO BREEZE, a pioneer in portable cooling solutions, is proud to announce the launch of its Mark 3 Portable Air Conditioner ('Mark 3') at the Consumer Electronic Show 2025 ('CES 2025') today. The revolutionary Mark 3 combines innovation and performance to deliver outdoor comfort for adventurers, professionals, and more. This game-changing cooling solution is perfect for a variety of outdoor scenarios, from leisurely activities to demanding work sites. Experience the ultimate in cooling technology, designed to enhance your comfort no matter where your adventures take you.

This Mark 3 is a cumulation of the latest advancements in portable air conditioning technology, offering powerful cooling packed in a convenient, lightweight, one-handed pickup design. Building on the foundational success of the Mark 2 Portable Air Conditioner ('Mark 2'), the Mark 3 is purpose-built to provide portable, efficient, and reliable cooling for on-the-go extended use. Powered by a unique micro twin-cylinder compressor, the Mark 3 operates at almost double the performance of its predecessor, boasting an impressive 5,280 BTU cooling capacity.

Weighing under 22 pounds (approx. 10kg), the Mark 3 is a faithful mobile cooling companion with the highest level of portability in the air conditioning space for open-air workers, track racers, van life dwellers, campers and semi-truck drivers  â€” anyone in need of effective climate control in compact spaces. Its sleek design and ergonomic handle ensure easy setup anywhere, anytime. Most importantly, the solid robust build of the Mark 3 allows it to perform in high-intensity and challenging environments such as construction sites and racing tracks.

More cooling for less energy

The Mark 3, equipped with spot cooling technology delivers air conditioning at an exceptionally energy-efficient rate that is perfect for outdoor usage. The swappable 1022Wh battery charges to 80% in just 2 hours, providing up to 7 hours of cool comfort on a single charge. For longer operation, you can connect additional power sources, such as a battery bank or portable power station, or link multiple batteries using the included power cable. With targeted spot cooling technology, the Mark 3 directs airflow precisely to the area or person that needs it. This not only ensures efficient cooling but also reduces overall energy consumption, making it both environmentally friendly and sustainable.

Adaptable climate control

Engineered with seven dynamic modes, including Rocket Mode for maximum cooling and Sleep Mode for quiet operation — the Mark 3 adapts to varied user needs for optimal performance and efficiency. It features a user-friendly climate control system that allows users to easily set any desired cooling temperature ranging between 61°F and 82°F. Environments ranging from 100 to 150 square feet are ideal for maximizing the cooling capabilities of the Mark 3.

Designed with comfort and convenience in mind

With a strong commitment to delivering convenient and comfortable cooling solutions for the great outdoors, ZERO BREEZE features a one-of-a-kind dual duct system that allows for peak efficiency in thermostatic control. Its condensation drain system also drains automatically, supported by a sensor and pump to prevent accidental spillage in campers and trucks.

"At ZERO BREEZE, instead of adapting the traditional air conditioners to more portable options, we are committed to innovation and creating solutions that are changing the way we experience the great outdoors," said Max Ma, Founder of ZERO BREEZE. "The Mark 3 represents the culmination of years of research and development, bringing users an unparalleled portable cooling solution across a diverse range of scenarios: from camping, truck traveling, construction sites and many more."

Availability:

The Mark 3 is now available for pre-order at a discount, coming to a total of only $1299.99. The first batch of units is expected to ship in late February based on the order sequence.

For more information about the Mark 3 and to place your pre-order, visit https://www.zerobreeze.com/products/zero-breeze-mark-3-ac. 

About ZERO BREEZE

Founded in 2016 and driven by a passion for innovation, ZERO BREEZE is a trailblazer in developing portable cooling solutions for adventurers, outdoor enthusiasts, and individuals seeking comfort in challenging environments.

Unlike traditional air conditioning units, which typically use standard compressors, ZERO BREEZE's portable air conditioners feature a unique micro twin-cylinder compressor. This design is specifically engineered to meet the needs of people on the move, providing efficient, portable cooling.  From portable air conditioners to versatile power sources, our solutions have applications beyond camping—serving patients, emergency teams, outdoor workers, race car drivers, and pets. This versatility showcases our commitment to enhancing comfort in any environment.

At ZERO BREEZE, our drive for innovation extends beyond our products; it's about making a positive impact on communities and the environment worldwide. Through a blend of creativity, functionality, and design, we strive to deliver solutions that provide cool comfort while inspiring a better way of living.

-end-

Media Contact: 

ZERO BREEZE

 

Selina Shi

Email: media@zerobreeze.com

TEAM LEWIS

 

Kate Kwan

Email: kate.kwan@teamlewis.com

 

Miranda Xie

Email: miranda.xie@teamlewis.com

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

ZERO BREEZE Unveils its Revolutionary Mark 3 Portable Air Conditioner at CES 2025

YANTAI, China, Jan. 8, 2025 /PRNewswire/ -- On Janurary 7th, 2025, Annals of Oncology (IF: 56.7), a top oncology journal globally, published remarkable long-term follow-up results of a phase 1b/2 clinical trial on Disitamab Vedotin (DV) (developed by Remegen Co., Ltd) combined with Toripalimab in treating locally advanced or metastatic urothelial carcinoma (la/mUC) (NCT04264936, study ID: RC48-C014). This trial was supervised by Professor Jun Guo and Professor Xi'nan Sheng's teams from Peking University Cancer Hospital.

It is the first time that long-term follow-up data has been released for a HER2-targeted antibody-drug conjugate (ADC) and PD-1 inhibitor combination therapy in treating la/mUC, marking it a significant milestone. The nearly-three-year follow-up data revealed an objective response rate (ORR) of 73.2% and median overall survival (OS) of 33.1 months, superior to data published from any other prospective clinical studies on ADC plus PD-1 combination therapies for la/mUC.

New Treatment Options for Patients with La/mUC

UC is the sixth most common cancer worldwide. GLOBOCAN 2022 estimated the year 2021 saw 614,298 new cases and 220,596 deaths of UC. In recent years, the prognosis for patients with la/mUC has significantly improved with new drugs and combination therapies approved, among which ADCs demonstrated outstanding potential.

As a HER2-targeted ADC, DV has been approved in China for patients with HER2-overexpressing (defined as immunohistochemistry [IHC] test results of 2+ or 3+) la/mUC previously treated with platinum-containing chemotherapy. The approval is based on the pooled results of two studies (NCT03507166 and NCT03809013, study IDs: RC48-C005 and RC48-C009) where the ORR registered 50.5% and the median duration of response (DOR) registered 7.3 months.

Multiple clinical studies on la/mUCin recent years have confirmed the synergistic antitumor effects of ADC combined with immunotherapy. NCT04264936 offered stronger evidence as its long-term follow-up results published in the Annals of Oncology demonstrated the high response rate, significant survival benefits, and manageable safety profile of the DV and Toripalimab combination therapy.

DV Combined with Toripalimab: High Response Rate and Prolonged Survival

NCT04264936 is an open-label, multicenter, investigator-initiated phase 1b/2 clinical trial investigating the safety and efficacy of DV in combination with Toripalimab for the treatment of patients with HER2-expressing la/mUC. The dose-escalation study (phase 1b) assessed two dose levels of DV (1.5 and 2.0 mg/kg) combined with Toripalimab (3.0 mg/kg) to determine the recommended phase 2 dose which was then evaluated in the dose-expansion stage (phase 2).

From August 2020 to December 2021, 41 patients were enrolled with a median age of 66 years. 53.7% of the participants were male, 70.7% had an ECOG performance status score of 1, 17 (41.5%) had lung metastasis, and 10 (24.4%) had liver metastasis.

As of March 1, 2024, among all participants, the ORR was 73.2% with 4 (9.8%) achieving complete response and 26 (63.4%) achieving partial response, the DCR was 90.2%, the median progression-free survival (PFS) was 9.3 months, the median DOR was 8.6 months, the median OS was 33.1 months and the 36-month OS rate was 49.2%.

Subgroup analysis revealed ORR benefits across all subgroups regardless of the number of prior lines of systemic treatments, HER2 expression (IHC 1+/2+/3+), and PD-L1 expression status. The ORRs for chemotherapy-naïve patients and those who progressed on platinum-based chemotherapy were 76.0% (19/25) and 68.8% (11/16), respectively. The ORRs for patients with HER2 IHC 3+, 2+, 1+, or 0 were 80.0%, 84.2%, 64.3%, and 33.3%, respectively. Compared with the three HER2 IHC 0 participants (one of whom achieved partial response), those with HER2 expression (IHC 1+/2+/3+) had a higher ORR (76.3% vs 33.3%) and longer PFS (median PFS: 9.3 vs 1.7 months).

In summary, the DV and Toripalimab combination therapy has preliminarily demonstrated promising efficacy and manageable safety profile among patients with la/mUC, wherein those with HER2 expression (IHC 1+/2+/3+) achieved high response rates and long-term survival benefits. These findings support the further exploration and validation of the benefits of DV combined with PD-1 inhibitors in treating la/mUC.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Published in Annals of Oncology: Disitamab Vedotin Combined with PD-1 Inhibitor is a Promising Treatment for Locally Advanced or Metastatic Urothelial Carcinoma